It is possible that in a daily dosing induction phase of IL-2 treatment, a combination of Treg desensitisation and Teff activation could increase insulitis and exacerbate T cell/cytokine-mediated destruction of β cells in T1D patients. Here, IL2 is linked to type 1 diabetes mellitus.